GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (FRA:VT6) » Definitions » Cyclically Adjusted Revenue per Share

Voyager Therapeutics (FRA:VT6) Cyclically Adjusted Revenue per Share : €2.08 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Voyager Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Voyager Therapeutics's adjusted revenue per share for the three months ended in Mar. 2025 was €0.103. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.08 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Voyager Therapeutics's average Cyclically Adjusted Revenue Growth Rate was -0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-20), Voyager Therapeutics's current stock price is €2.912. Voyager Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €2.08. Voyager Therapeutics's Cyclically Adjusted PS Ratio of today is 1.40.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Voyager Therapeutics was 4.34. The lowest was 1.45. And the median was 2.96.


Voyager Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Voyager Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics Cyclically Adjusted Revenue per Share Chart

Voyager Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 2.10

Voyager Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 1.97 1.91 2.10 2.08

Competitive Comparison of Voyager Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Voyager Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Cyclically Adjusted PS Ratio falls into.


;
;

Voyager Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Voyager Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.103/134.9266*134.9266
=0.103

Current CPI (Mar. 2025) = 134.9266.

Voyager Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.296 100.684 0.397
201509 0.171 100.392 0.230
201512 0.182 99.792 0.246
201603 0.173 100.470 0.232
201606 0.131 101.688 0.174
201609 0.116 101.861 0.154
201612 0.088 101.863 0.117
201703 0.053 102.862 0.070
201706 0.040 103.349 0.052
201709 0.037 104.136 0.048
201712 0.183 104.011 0.237
201803 0.024 105.290 0.031
201806 0.069 106.317 0.088
201809 0.056 106.507 0.071
201812 0.055 105.998 0.070
201903 0.138 107.251 0.174
201906 1.075 108.070 1.342
201909 0.505 108.329 0.629
201912 0.798 108.420 0.993
202003 0.442 108.902 0.548
202006 0.688 108.767 0.853
202009 2.656 109.815 3.263
202012 0.144 109.897 0.177
202103 0.146 111.754 0.176
202106 0.030 114.631 0.035
202109 0.033 115.734 0.038
202112 0.657 117.630 0.754
202203 0.016 121.301 0.018
202206 0.018 125.017 0.019
202209 1.049 125.227 1.130
202212 -0.038 125.222 -0.041
202303 3.334 127.348 3.532
202306 0.103 128.729 0.108
202309 0.099 129.860 0.103
202312 1.637 129.419 1.707
202403 0.314 131.776 0.322
202406 0.476 132.554 0.485
202409 0.384 133.029 0.389
202412 0.103 133.157 0.104
202503 0.103 134.927 0.103

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Voyager Therapeutics  (FRA:VT6) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Voyager Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.912/2.08
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Voyager Therapeutics was 4.34. The lowest was 1.45. And the median was 2.96.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Voyager Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyager Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Voyager Therapeutics Headlines

No Headlines